Spironolactone is the first mineralocorticoid receptor antagonist developed and is widely used in the treatment of hypertension, primary hyperaldosteronism, and peripheral edema associated with heart failure, as well as other conditions related to aldosteronism [1]. The gene discussed is NR3C2; the disease is hypertensive disorder.